Trial Profile
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR0532 Tablets in Healthy Subjects
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs SHR-0532 (Primary)
- Indications Hypertension
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 30 Aug 2018 New trial record